Narcolepsy
RecruitingEfficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1
- Disease:Narcolepsy
- Substances:Alks 2680
France- Participants:18–64 years · 65+ years
- Substances:Alks 2680
- Sponsor:Alkermes Inc.
Rare diseases
Investigational molecules
Locations
Back to France604 clinical trials in Saint-Herblain, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in FranceEssaisCliniques.fr(opens in a new tab)
France
France
France
France
France
France
France
France
France
France
France
FranceThe busiest research cities in the country
What the registry says about research in the country
Innovative clinical trials focusing on advanced cancer treatments, including studies for breast cancer, lung cancer, and gastric cancer. Research includes novel therapeutic approaches targeting specific cancer types.
Several trials are evaluating new antibody-drug conjugates and combination therapies for metastatic diseases.
Studies targeting various neurological conditions, with emphasis on frontotemporal dementia and multiple sclerosis. Research focuses on innovative therapeutic approaches and disease-modifying treatments.
Trials include evaluation of novel antibodies and assessment of long-term treatment efficacy.
Comprehensive research into heart failure prevention, pulmonary hypertension, and cardiac rhythm disorders. Studies focus on innovative therapeutic approaches and preventive measures.
Research includes long-term safety assessments and combination therapy evaluations.
Tell us about your condition – we search every trial in Europe and connect you with the right site.